Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium

被引:6
|
作者
Krzywdzinska, Agnieszka [1 ]
Pula, Bartosz [2 ]
Czyz, Anna [3 ]
Krzymieniewska, Beata [1 ]
Kiernicka-Parulska, Jolanta [4 ]
Mierzwa, Anna [4 ]
Szymczak, Donata [5 ]
Milanowska, Aneta [5 ]
Kiraga, Aleksandra [5 ]
Kwiecien, Iwona [6 ]
Zaleska, Joanna [7 ]
Jamroziak, Krzysztof [8 ]
机构
[1] Inst Hematol & Transfus Med, Lab Immunophenotyping, PL-02776 Warsaw, Poland
[2] Inst Hematol & Transfus Med, Dept Hematol, PL-02776 Warsaw, Poland
[3] Wroclaw Med Univ, Dept Hematol & Bone Marrow Transplantat, PL-50367 Wroclaw, Poland
[4] Univ Hosp Lords Transfigurat, Dept Haematol & Bone Marrow Transplantat, Flow Cytometry Lab, Haematol Clin Lab, PL-60101 Poznan, Poland
[5] Univ Hosp Wroclaw, Dept & Clin Haematol Blood Neoplasms & Bone Marro, Flow Cytometry & Cytomorphol Lab, PL-50367 Wroclaw, Poland
[6] Mil Inst Med, Dept Internal Med & Hematol, Lab Hematol & Flow Cytometry, PL-04141 Warsaw, Poland
[7] Med Univ Lublin, Dept Expt Hematooncol, PL-20059 Lublin, Poland
[8] Med Univ Warsaw, Dept Hematol Transplantat & Internal Med, PL-02097 Warsaw, Poland
关键词
multiple myeloma; minimal residual disease; flow cytometry; CONSENSUS GUIDELINES; DARATUMUMAB THERAPY; SURVIVAL OUTCOMES; MRD DETECTION; PLASMA-CELLS; SINGLE-TUBE; STANDARDIZATION; CD38;
D O I
10.3390/diagnostics11101872
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Minimal residual disease (MRD) status is now considered as one of the most relevant prognostic factors in multiple myeloma (MM) while MRD negativity became an important endpoint in clinical trials. Here, we report the results of the first study evaluating the reproducibility of high-sensitivity flow cytometry MM MRD assessment in four laboratories in Poland. EuroFlow protocols for instrument setting standardization and sample preparation in MM MRD assessment were implemented in each laboratory. In the inter-laboratory reproducibility study, 12 bone marrow samples from MM patients were distributed and processed in participant laboratories. In the inter-operator concordance study, 13 raw data files from MM MRD measurements were analyzed by five independent operators. The inter-laboratory study showed high 95% overall concordance of results among laboratories. In the inter-operator study, 89% of MRD results reported were concordant, and the highest immunophenotype interpretation differences with regard to expression of CD27, CD45, CD81 were noticed. We confirmed the applicability and feasibility of the EuroFlow protocol as a highly sensitive method of MRD evaluation in MM. Results of our inter-center comparison study demonstrate that the standardization of MM MRD assessment protocols is highly desirable to improve quality and comparability of results within and between different clinical trials.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Flow Cytometric Immunophenotyping and Minimal Residual Disease Analysis in Multiple Myeloma
    Gupta, Ritu
    Bhaskar, Archana
    Kumar, Lalit
    Sharma, Atul
    Jain, Paresh
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 132 (05) : 728 - 732
  • [2] Flow Cytometric Immunophenotyping for Minimal Residual Disease Analysis in Multiple Myeloma.
    Gupta, Rita
    Bhaskar, Archana
    Jain, Paresh
    Sharma, Atul
    Kumar, Lalit
    BLOOD, 2008, 112 (11) : 937 - 937
  • [3] International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
    Luciano J. Costa
    Benjamin A. Derman
    Susan Bal
    Surbhi Sidana
    Saurabh Chhabra
    Rebecca Silbermann
    Jing C. Ye
    Gordon Cook
    Robert F. Cornell
    Sarah A. Holstein
    Qian Shi
    James Omel
    Natalie S. Callander
    Wee Joo Chng
    Vania Hungria
    Angelo Maiolino
    Edward Stadtmauer
    Sergio Giralt
    Marcelo Pasquini
    Andrzej J. Jakubowiak
    Gareth J. Morgan
    Amrita Krishnan
    Graham H. Jackson
    Mohamad Mohty
    Maria Victoria Mateos
    Meletious A. Dimopoulos
    Thierry Facon
    Andrew Spencer
    Jesus San Miguel
    Parameswaran Hari
    Saad Z. Usmani
    Salomon Manier
    Phillip McCarthy
    Shaji Kumar
    Francesca Gay
    Bruno Paiva
    Leukemia, 2021, 35 : 18 - 30
  • [4] International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
    Costa, Luciano J.
    Derman, Benjamin A.
    Bal, Susan
    Sidana, Surbhi
    Chhabra, Saurabh
    Silbermann, Rebecca
    Ye, Jing C.
    Cook, Gordon
    Cornell, Robert F.
    Holstein, Sarah A.
    Shi, Qian
    Omel, James
    Callander, Natalie S.
    Chng, Wee Joo
    Hungria, Vania
    Maiolino, Angelo
    Stadtmauer, Edward
    Giralt, Sergio
    Pasquini, Marcelo
    Jakubowiak, Andrzej J.
    Morgan, Gareth J.
    Krishnan, Amrita
    Jackson, Graham H.
    Mohty, Mohamad
    Mateos, Maria Victoria
    Dimopoulos, Meletious A.
    Facon, Thierry
    Spencer, Andrew
    San Miguel, Jesus
    Hari, Parameswaran
    Usmani, Saad Z.
    Manier, Salomon
    McCarthy, Phillip
    Kumar, Shaji
    Gay, Francesca
    Paiva, Bruno
    LEUKEMIA, 2021, 35 (01) : 18 - 30
  • [5] Minimal residual disease monitoring in multiple myeloma:: How specific is the flow cytometric analysis?
    Lioznov, M.
    Fehse, B.
    Zander, A.
    Kroeger, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 203 - 203
  • [6] Introduction to Multiple Myeloma Special Issue: The Flow Cytometric Detection of Minimal Residual Disease
    Preffer, Frederic I.
    Yuan, Constance M.
    Lin, Pei
    Stetler-Stevenson, MaryAlice
    Marti, Gerald E.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2016, 90 (01) : 9 - 13
  • [7] Role of minimal residual disease assessment in multiple myeloma
    Szalat, Raphael E.
    Anderson, Kenneth C.
    Munshi, Nikhil C.
    HAEMATOLOGICA, 2024, 109 (07) : 2049 - 2059
  • [8] Role of minimal residual disease assessment in multiple myeloma
    Szalat, Raphael E.
    Anderson, Kenneth C.
    Munshi, Nikhil C.
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 2049 - 2059
  • [9] FLOW CYTOMETRIC ANALYSIS AND MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA: A COMPARISON BETWEEN FLOW CYTOMETRIC IMMUNOPHENOTYPING AND CYCLOSCOPE-MG.
    De Tullio, G.
    Ria, R.
    Reale, A.
    Minoia, C.
    Serrati, S.
    Loseto, G.
    Vacca, A.
    Guarini, A.
    HAEMATOLOGICA, 2013, 98 : 337 - 337
  • [10] Minimal Residual Disease in Multiple Myeloma
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) : 2523 - 2526